Ewha Institute of Convergence Medicine was established in April 2012 to develop high technology that control refractory diseases such as cancers, cardiovascular diseases, immune-mediated inflammatory diseases, metabolic diseases, and antibiotic resistant infectious diseases.

The institute aims to develop innovative techniques for the diagnosis and treatment of refractory diseases through convergence of research, development, and business (R&DB). It is composed of translational research center, product development center, and clinical trial center to achieve the convergence of R&DB.